In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,866 clinical isolates obtained from 72 centers in 2010

Keizo Yamaguchi; Akira Ohno; Yoshikazu Ishii; Kazuhiro Tateda; Morihiro Iwata; Kouji Akizawa; Chikara Shimizu; Tasuku Hayashi; Mitsuo Kaku; Hiroyuki Kunishima; Miho Kitagawa; Makoto Miki; Chizuko Kawamura; Minoru Yasujima; Hiromi Tashiro; Hiroko Horiuchi; Yosei Katayama; Akira Suwabe; Makiko Kurota; Kenji Kikuchi; Satoru Kuroki; Katsu Hirayama; Toshiaki Takahashi; Takanori Gotou; Keita Morikane; Reiko Ota; Takuo Nakagawa; Kyoji Moriya; Mitsuru Murata; Akiko Yoneyama; Shigemi Kondou; Shigeki Misawa; Imao Sekine; Joji Shiotani; Tomohiro Nakayama; Michiko Yagoshi; Hajime Horiuchi; Yoko Tazawa; Harushige Kanno; Masanori Aihara; Kenichiro Yamazaki; Hideyuki Okamoto; Kosuke Haruki; Junko Yazawa; Eiko Nagano; Motoi Okada; Yasuko Fukuda; Hiromi Ikari; Shigefumi Maesaki; Giichi Hashikita; Midori Sumitomo; Eiji Miyajima; Takefumi Saito; Nobuyuki Taniguchi; Akira Hishinuma; Yoshitaka Yamamoto; Yuki Okamoto; Nobuo Yamane; Ryou Maruyama; Chieko Kawashima; Masami Murakami; Sachie Yomoda; Tetsuo Machida; Yukio Ozaki; Takashi Uchida; Hisashi Baba; Yasuyuki Sugiura; Konomi Kondo; Takako Yamada; Hideo Gonda; Ikuo Yamaguchi; Toshiyuki Akahori; Keiichi Uemura; Masato Maekawa; Hitoshi Yoshimura; Kaname Nakatani; Yoshiko Matsushima; Tsutomu Nobori; Yoshinori Fujimoto; Yuko Asano; Asami Morinaga; Shinichi Fujita; Yasuko Senda; Yukio Hida; Masanori Yamashita; Haruyoshi Yoshida; Satoshi Ichiyama; Hidetoshi Okabe; Masayo Shigeta; Kaoru Shimizu; Hiroya Masaki; Hitoshi Heijyou; Hideo Nakaya; Takayuki Takubo; Tadashi Kusakabe; Tomonori Higashiyama; Hiroko Yoshida; Hiroshi Morishita; Shuji Matsuo; Hisashi Kono; Saori Fukuda; Reiko Sano; Yosuke Yuzuki; Norio Ikeda; Masaya Idomuki; Go Yamamoto; Syohiro Kinoshita; Seiji Kawano; Masao Doi; Yaeko Watanabe; Satomi Shimizu; Mikio Oka; Yoshihiro Kobashi; Nobuchika Kusano; Hiromitsu Fujiwara; Hiromi Murota; Shota Morishita; Atsushi Nagai; Hidehiko Moriyama; Yuki Taniguchi; Kiyoshi Negayama; Koji Murao; Hitoshi Miyamoto; Tetsuro Sugiura; Tamae Morita; Hiromi Tou; Akira Matsunaga; Dongchon Kang; Makiko Kiyosuke; Koichi Mashiba; Katsunori Yanagihara; Junichi Matsuda; Shigeru Kohno; Yosuke Aoki; Zenzo Nagasawa; Koji Kusaba; Kazufumi Hiramatsu; Tetsunori Saikawa; Hiroaki Miyanohara; Yuji Saeki; Ichiro Takajo; Akihiko Okayama; Nobuhisa Yamane; Isamu Nakasone

In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,866 clinical isolates obtained from 72 centers in 2010

Keizo Yamaguchi, Akira Ohno, Yoshikazu Ishii, Kazuhiro Tateda, Morihiro Iwata, Kouji Akizawa, Chikara Shimizu, Tasuku Hayashi, Mitsuo Kaku, Hiroyuki Kunishima, Miho Kitagawa, Makoto Miki, Chizuko Kawamura, Minoru Yasujima, Hiromi Tashiro, Hiroko Horiuchi, Yosei Katayama, Akira Suwabe, Makiko Kurota, Kenji KikuchiSatoru Kuroki, Katsu Hirayama, Toshiaki Takahashi, Takanori Gotou, Keita Morikane, Reiko Ota, Takuo Nakagawa, Kyoji Moriya, Mitsuru Murata, Akiko Yoneyama, Shigemi Kondou, Shigeki Misawa, Imao Sekine, Joji Shiotani, Tomohiro Nakayama, Michiko Yagoshi, Hajime Horiuchi, Yoko Tazawa, Harushige Kanno, Masanori Aihara, Kenichiro Yamazaki, Hideyuki Okamoto, Kosuke Haruki, Junko Yazawa, Eiko Nagano, Motoi Okada, Yasuko Fukuda, Hiromi Ikari, Shigefumi Maesaki, Giichi Hashikita, Midori Sumitomo, Eiji Miyajima, Takefumi Saito, Nobuyuki Taniguchi, Akira Hishinuma, Yoshitaka Yamamoto, Yuki Okamoto, Nobuo Yamane, Ryou Maruyama, Chieko Kawashima, Masami Murakami, Sachie Yomoda, Tetsuo Machida, Yukio Ozaki, Takashi Uchida, Hisashi Baba, Yasuyuki Sugiura, Konomi Kondo, Takako Yamada, Hideo Gonda, Ikuo Yamaguchi, Toshiyuki Akahori, Keiichi Uemura, Masato Maekawa, Hitoshi Yoshimura, Kaname Nakatani, Yoshiko Matsushima, Tsutomu Nobori, Yoshinori Fujimoto, Yuko Asano, Asami Morinaga, Shinichi Fujita, Yasuko Senda, Yukio Hida, Masanori Yamashita, Haruyoshi Yoshida, Satoshi Ichiyama, Hidetoshi Okabe, Masayo Shigeta, Kaoru Shimizu, Hiroya Masaki, Hitoshi Heijyou, Hideo Nakaya, Takayuki Takubo, Tadashi Kusakabe, Tomonori Higashiyama, Hiroko Yoshida, Hiroshi Morishita, Shuji Matsuo, Hisashi Kono, Saori Fukuda, Reiko Sano, Yosuke Yuzuki, Norio Ikeda, Masaya Idomuki, Go Yamamoto, Syohiro Kinoshita, Seiji Kawano, Masao Doi, Yaeko Watanabe, Satomi Shimizu, Mikio Oka, Yoshihiro Kobashi, Nobuchika Kusano, Hiromitsu Fujiwara, Hiromi Murota, Shota Morishita, Atsushi Nagai, Hidehiko Moriyama, Yuki Taniguchi, Kiyoshi Negayama, Koji Murao, Hitoshi Miyamoto, Tetsuro Sugiura, Tamae Morita, Hiromi Tou, Akira Matsunaga, Dongchon Kang, Makiko Kiyosuke, Koichi Mashiba, Katsunori Yanagihara, Junichi Matsuda, Shigeru Kohno, Yosuke Aoki, Zenzo Nagasawa, Koji Kusaba, Kazufumi Hiramatsu, Tetsunori Saikawa, Hiroaki Miyanohara, Yuji Saeki, Ichiro Takajo, Akihiko Okayama, Nobuhisa Yamane, Isamu Nakasone

研究成果: Review article › 査読

26 被引用数 (Scopus)

抄録

Postmarketing surveillance of levofloxacin (LVFX) has been conducted continuously since 1992. The present survey was performed to investigate in vitro susceptibility of recent clinical isolates in Japan to 30 selected antibacterial agents, focusing on fluoroquinolones (FQs). The common respiratory pathogens Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae continue to show a high susceptibility to FQs. In contrast, widely-prevailing resistance to macrolides was markedly noted among S. pneumoniae and S. pyogenes. Regarding H. influenzae, the prevalence of β-lactamase-negative ampicillin-resistant isolates has been increasing year by year (25.8% in 2002, 40.0% in 2004, 50.1% in 2007, and 57.9% in 2010). Enterobacteriaceae showed high susceptibility to FQs, however, prevalence of LVFX-resistant Escherichia coli, including intermediate resistance, was 29.3%, showing an increase over time. Nevertheless, the increase in the prevalence of LVFX-resistant E. coli isolates has slowed since 2007 (8.2% in 2000, 11.8% in 2002, 18.8% in 2004, 26.2% in 2007, and 29.3% in 2010), suggesting the influence of LVFX 500 mg tablets since its approval in 2009. Another Enterobacteriaceae member, Klebsiella pneumoniae, showed low resistance to FQs, in contrast with E. coli. In methicillin-resistant Staphylococcus aureus (MRSA), the percentage of FQ-susceptible isolates was low, at 51.6% for susceptibility to sitafloxacin, and at only around 10% for susceptibility to other FQs. However, methicillin-susceptible S. aureus (MSSA) isolates were highly susceptible to FQs, with the percentage ranging from 88.5% to 99.1%. The prevalence of FQs-resistant isolates in methicillin-resistant coagulase-negative staphylococci was higher than that in methicillin-susceptible coagulase-negative staphylococci, although it was lower than the prevalence of FQ-resistance in MRSA. The prevalence of FQs-resistant Pseudomonas aeruginosa isolates derived from urinary tract infections (UTIs) was 15.4-21.3%, higher than the prevalence of 6.1-12.3% in P. aeruginosa isolates from respiratory tract infections (RTIs). While this trend was consistent with the results of previous surveillance, gradual decreases were noted in the prevalence of FQ-resistant P. aeruginosa isolates derived from UTIs. The prevalence of multidrug-resistant P. aeruginosa was 2.3% among isolates derived from UTIs and 0.3% among isolates from RTIs, a decrease from the results of 2007, Acinetobacter spp. showed high susceptibility to FQs. Imipenem-resistant Acinetobacter baumannii, which is currently an emerging issue, was detected at a prevalence of 2.4% (13 isolates). Neisseria gonorrhoeae showed a high resistance of 81.3-82.5%, to FQs. Ceftriaxone (CTRX) continued to show 100% susceptibility until 2007, but the present survey revealed the advent of resistance to CTRX in some clinical isolates. The result of the present survey indicated that although methicillin-resistant staphylococci, Enterococcus faecium, P. aeruginosa from UTIs, N. gonorrhoeae, and E. coli showed resistance of about 20% or more (19.5-89.2%) against the FQs which have been used clinically for over 17 years, the trends observed were similar to the results of previous surveillance. While FQ resistance has been prevailing in E. coli, E. coli still shows more than 70% susceptibility to FQs. The other bacterial species maintained high susceptibility rates of greater than 80%, against FQs.

本文言語	English
ページ（範囲）	181-206
ページ数	26
ジャーナル	Japanese Journal of Antibiotics
巻	65
号	3
出版ステータス	Published - 2012 6月
外部発表	はい

ASJC Scopus subject areas

微生物学（医療）
薬理学（医学）
感染症

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

他のファイルとリンク

フィンガープリント

「In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,866 clinical isolates obtained from 72 centers in 2010」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Yamaguchi, K., Ohno, A., Ishii, Y., Tateda, K., Iwata, M., Akizawa, K., Shimizu, C., Hayashi, T., Kaku, M., Kunishima, H., Kitagawa, M., Miki, M., Kawamura, C., Yasujima, M., Tashiro, H., Horiuchi, H., Katayama, Y., Suwabe, A., Kurota, M., ... Nakasone, I. (2012). In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,866 clinical isolates obtained from 72 centers in 2010. Japanese Journal of Antibiotics, 65(3), 181-206.

Yamaguchi, K, Ohno, A, Ishii, Y, Tateda, K, Iwata, M, Akizawa, K, Shimizu, C, Hayashi, T, Kaku, M, Kunishima, H, Kitagawa, M, Miki, M, Kawamura, C, Yasujima, M, Tashiro, H, Horiuchi, H, Katayama, Y, Suwabe, A, Kurota, M, Kikuchi, K, Kuroki, S, Hirayama, K, Takahashi, T, Gotou, T, Morikane, K, Ota, R, Nakagawa, T, Moriya, K, Murata, M, Yoneyama, A, Kondou, S, Misawa, S, Sekine, I, Shiotani, J, Nakayama, T, Yagoshi, M, Horiuchi, H, Tazawa, Y, Kanno, H, Aihara, M, Yamazaki, K, Okamoto, H, Haruki, K, Yazawa, J, Nagano, E, Okada, M, Fukuda, Y, Ikari, H, Maesaki, S, Hashikita, G, Sumitomo, M, Miyajima, E, Saito, T, Taniguchi, N, Hishinuma, A, Yamamoto, Y, Okamoto, Y, Yamane, N, Maruyama, R, Kawashima, C, Murakami, M, Yomoda, S, Machida, T, Ozaki, Y, Uchida, T, Baba, H, Sugiura, Y, Kondo, K, Yamada, T, Gonda, H, Yamaguchi, I, Akahori, T, Uemura, K, Maekawa, M, Yoshimura, H, Nakatani, K, Matsushima, Y, Nobori, T, Fujimoto, Y, Asano, Y, Morinaga, A, Fujita, S, Senda, Y, Hida, Y, Yamashita, M, Yoshida, H, Ichiyama, S, Okabe, H, Shigeta, M, Shimizu, K, Masaki, H, Heijyou, H, Nakaya, H, Takubo, T, Kusakabe, T, Higashiyama, T, Yoshida, H, Morishita, H, Matsuo, S, Kono, H, Fukuda, S, Sano, R, Yuzuki, Y, Ikeda, N, Idomuki, M, Yamamoto, G, Kinoshita, S, Kawano, S, Doi, M, Watanabe, Y, Shimizu, S, Oka, M, Kobashi, Y, Kusano, N, Fujiwara, H, Murota, H, Morishita, S, Nagai, A, Moriyama, H, Taniguchi, Y, Negayama, K, Murao, K, Miyamoto, H, Sugiura, T, Morita, T, Tou, H, Matsunaga, A, Kang, D, Kiyosuke, M, Mashiba, K, Yanagihara, K, Matsuda, J, Kohno, S, Aoki, Y, Nagasawa, Z, Kusaba, K, Hiramatsu, K, Saikawa, T, Miyanohara, H, Saeki, Y, Takajo, I, Okayama, A, Yamane, N & Nakasone, I 2012, 'In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,866 clinical isolates obtained from 72 centers in 2010', Japanese Journal of Antibiotics, vol. 65, no. 3, pp. 181-206.

@article{db676f3412e74c9aaefd95978a18214f,

title = "In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,866 clinical isolates obtained from 72 centers in 2010",

abstract = "Postmarketing surveillance of levofloxacin (LVFX) has been conducted continuously since 1992. The present survey was performed to investigate in vitro susceptibility of recent clinical isolates in Japan to 30 selected antibacterial agents, focusing on fluoroquinolones (FQs). The common respiratory pathogens Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae continue to show a high susceptibility to FQs. In contrast, widely-prevailing resistance to macrolides was markedly noted among S. pneumoniae and S. pyogenes. Regarding H. influenzae, the prevalence of β-lactamase-negative ampicillin-resistant isolates has been increasing year by year (25.8% in 2002, 40.0% in 2004, 50.1% in 2007, and 57.9% in 2010). Enterobacteriaceae showed high susceptibility to FQs, however, prevalence of LVFX-resistant Escherichia coli, including intermediate resistance, was 29.3%, showing an increase over time. Nevertheless, the increase in the prevalence of LVFX-resistant E. coli isolates has slowed since 2007 (8.2% in 2000, 11.8% in 2002, 18.8% in 2004, 26.2% in 2007, and 29.3% in 2010), suggesting the influence of LVFX 500 mg tablets since its approval in 2009. Another Enterobacteriaceae member, Klebsiella pneumoniae, showed low resistance to FQs, in contrast with E. coli. In methicillin-resistant Staphylococcus aureus (MRSA), the percentage of FQ-susceptible isolates was low, at 51.6% for susceptibility to sitafloxacin, and at only around 10% for susceptibility to other FQs. However, methicillin-susceptible S. aureus (MSSA) isolates were highly susceptible to FQs, with the percentage ranging from 88.5% to 99.1%. The prevalence of FQs-resistant isolates in methicillin-resistant coagulase-negative staphylococci was higher than that in methicillin-susceptible coagulase-negative staphylococci, although it was lower than the prevalence of FQ-resistance in MRSA. The prevalence of FQs-resistant Pseudomonas aeruginosa isolates derived from urinary tract infections (UTIs) was 15.4-21.3%, higher than the prevalence of 6.1-12.3% in P. aeruginosa isolates from respiratory tract infections (RTIs). While this trend was consistent with the results of previous surveillance, gradual decreases were noted in the prevalence of FQ-resistant P. aeruginosa isolates derived from UTIs. The prevalence of multidrug-resistant P. aeruginosa was 2.3% among isolates derived from UTIs and 0.3% among isolates from RTIs, a decrease from the results of 2007, Acinetobacter spp. showed high susceptibility to FQs. Imipenem-resistant Acinetobacter baumannii, which is currently an emerging issue, was detected at a prevalence of 2.4% (13 isolates). Neisseria gonorrhoeae showed a high resistance of 81.3-82.5%, to FQs. Ceftriaxone (CTRX) continued to show 100% susceptibility until 2007, but the present survey revealed the advent of resistance to CTRX in some clinical isolates. The result of the present survey indicated that although methicillin-resistant staphylococci, Enterococcus faecium, P. aeruginosa from UTIs, N. gonorrhoeae, and E. coli showed resistance of about 20% or more (19.5-89.2%) against the FQs which have been used clinically for over 17 years, the trends observed were similar to the results of previous surveillance. While FQ resistance has been prevailing in E. coli, E. coli still shows more than 70% susceptibility to FQs. The other bacterial species maintained high susceptibility rates of greater than 80%, against FQs.",

author = "Keizo Yamaguchi and Akira Ohno and Yoshikazu Ishii and Kazuhiro Tateda and Morihiro Iwata and Kouji Akizawa and Chikara Shimizu and Tasuku Hayashi and Mitsuo Kaku and Hiroyuki Kunishima and Miho Kitagawa and Makoto Miki and Chizuko Kawamura and Minoru Yasujima and Hiromi Tashiro and Hiroko Horiuchi and Yosei Katayama and Akira Suwabe and Makiko Kurota and Kenji Kikuchi and Satoru Kuroki and Katsu Hirayama and Toshiaki Takahashi and Takanori Gotou and Keita Morikane and Reiko Ota and Takuo Nakagawa and Kyoji Moriya and Mitsuru Murata and Akiko Yoneyama and Shigemi Kondou and Shigeki Misawa and Imao Sekine and Joji Shiotani and Tomohiro Nakayama and Michiko Yagoshi and Hajime Horiuchi and Yoko Tazawa and Harushige Kanno and Masanori Aihara and Kenichiro Yamazaki and Hideyuki Okamoto and Kosuke Haruki and Junko Yazawa and Eiko Nagano and Motoi Okada and Yasuko Fukuda and Hiromi Ikari and Shigefumi Maesaki and Giichi Hashikita and Midori Sumitomo and Eiji Miyajima and Takefumi Saito and Nobuyuki Taniguchi and Akira Hishinuma and Yoshitaka Yamamoto and Yuki Okamoto and Nobuo Yamane and Ryou Maruyama and Chieko Kawashima and Masami Murakami and Sachie Yomoda and Tetsuo Machida and Yukio Ozaki and Takashi Uchida and Hisashi Baba and Yasuyuki Sugiura and Konomi Kondo and Takako Yamada and Hideo Gonda and Ikuo Yamaguchi and Toshiyuki Akahori and Keiichi Uemura and Masato Maekawa and Hitoshi Yoshimura and Kaname Nakatani and Yoshiko Matsushima and Tsutomu Nobori and Yoshinori Fujimoto and Yuko Asano and Asami Morinaga and Shinichi Fujita and Yasuko Senda and Yukio Hida and Masanori Yamashita and Haruyoshi Yoshida and Satoshi Ichiyama and Hidetoshi Okabe and Masayo Shigeta and Kaoru Shimizu and Hiroya Masaki and Hitoshi Heijyou and Hideo Nakaya and Takayuki Takubo and Tadashi Kusakabe and Tomonori Higashiyama and Hiroko Yoshida and Hiroshi Morishita and Shuji Matsuo and Hisashi Kono and Saori Fukuda and Reiko Sano and Yosuke Yuzuki and Norio Ikeda and Masaya Idomuki and Go Yamamoto and Syohiro Kinoshita and Seiji Kawano and Masao Doi and Yaeko Watanabe and Satomi Shimizu and Mikio Oka and Yoshihiro Kobashi and Nobuchika Kusano and Hiromitsu Fujiwara and Hiromi Murota and Shota Morishita and Atsushi Nagai and Hidehiko Moriyama and Yuki Taniguchi and Kiyoshi Negayama and Koji Murao and Hitoshi Miyamoto and Tetsuro Sugiura and Tamae Morita and Hiromi Tou and Akira Matsunaga and Dongchon Kang and Makiko Kiyosuke and Koichi Mashiba and Katsunori Yanagihara and Junichi Matsuda and Shigeru Kohno and Yosuke Aoki and Zenzo Nagasawa and Koji Kusaba and Kazufumi Hiramatsu and Tetsunori Saikawa and Hiroaki Miyanohara and Yuji Saeki and Ichiro Takajo and Akihiko Okayama and Nobuhisa Yamane and Isamu Nakasone",

note = "Funding Information: * Associate Professor, Mississippi College School of Law. Many thanks to Professors Miriam Baer, Tamara Belinfanti, Mercer Bullard, Lisa Fairfax, Michelle Harner, Joan Heminway, Andrew Lund, Veronica Root, Victoria Shannon Sahani, Maurice Stucke, and Charles Yablon for their helpful input on an earlier draft of this paper during our Corporate Compliance Discussion Group at the 2014 Southeastern Association of Law Schools Annual Meeting. I offer a special thanks to Associate Professor Gregory Gilchrist and Assistant Professor Andrew Verstein for their detailed comments and suggestions, which have improved the Article immensely. I would also like to thank my research assistants, Jhasmine Andrews, Matthew Rich, Laura Barton, and Rita Santibanez for their excellent work on this project. Finally, I thank Mississippi College School of Law for the generous financial support provided for this project.",

year = "2012",

month = jun,

language = "English",

volume = "65",

pages = "181--206",

journal = "Japanese Journal of Antibiotics",

issn = "0368-2781",

publisher = "Japan Antibiotics Research Association",

number = "3",

}

TY - JOUR

T1 - In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,866 clinical isolates obtained from 72 centers in 2010

AU - Yamaguchi, Keizo

AU - Ohno, Akira

AU - Ishii, Yoshikazu

AU - Tateda, Kazuhiro

AU - Iwata, Morihiro

AU - Akizawa, Kouji

AU - Shimizu, Chikara

AU - Hayashi, Tasuku

AU - Kaku, Mitsuo

AU - Kunishima, Hiroyuki

AU - Kitagawa, Miho

AU - Miki, Makoto

AU - Kawamura, Chizuko

AU - Yasujima, Minoru

AU - Tashiro, Hiromi

AU - Horiuchi, Hiroko

AU - Katayama, Yosei

AU - Suwabe, Akira

AU - Kurota, Makiko

AU - Kikuchi, Kenji

AU - Kuroki, Satoru

AU - Hirayama, Katsu

AU - Takahashi, Toshiaki

AU - Gotou, Takanori

AU - Morikane, Keita

AU - Ota, Reiko

AU - Nakagawa, Takuo

AU - Moriya, Kyoji

AU - Murata, Mitsuru

AU - Yoneyama, Akiko

AU - Kondou, Shigemi

AU - Misawa, Shigeki

AU - Sekine, Imao

AU - Shiotani, Joji

AU - Nakayama, Tomohiro

AU - Yagoshi, Michiko

AU - Horiuchi, Hajime

AU - Tazawa, Yoko

AU - Kanno, Harushige

AU - Aihara, Masanori

AU - Yamazaki, Kenichiro

AU - Okamoto, Hideyuki

AU - Haruki, Kosuke

AU - Yazawa, Junko

AU - Nagano, Eiko

AU - Okada, Motoi

AU - Fukuda, Yasuko

AU - Ikari, Hiromi

AU - Maesaki, Shigefumi

AU - Hashikita, Giichi

AU - Sumitomo, Midori

AU - Miyajima, Eiji

AU - Saito, Takefumi

AU - Taniguchi, Nobuyuki

AU - Hishinuma, Akira

AU - Yamamoto, Yoshitaka

AU - Okamoto, Yuki

AU - Yamane, Nobuo

AU - Maruyama, Ryou

AU - Kawashima, Chieko

AU - Murakami, Masami

AU - Yomoda, Sachie

AU - Machida, Tetsuo

AU - Ozaki, Yukio

AU - Uchida, Takashi

AU - Baba, Hisashi

AU - Sugiura, Yasuyuki

AU - Kondo, Konomi

AU - Yamada, Takako

AU - Gonda, Hideo

AU - Yamaguchi, Ikuo

AU - Akahori, Toshiyuki

AU - Uemura, Keiichi

AU - Maekawa, Masato

AU - Yoshimura, Hitoshi

AU - Nakatani, Kaname

AU - Matsushima, Yoshiko

AU - Nobori, Tsutomu

AU - Fujimoto, Yoshinori

AU - Asano, Yuko

AU - Morinaga, Asami

AU - Fujita, Shinichi

AU - Senda, Yasuko

AU - Hida, Yukio

AU - Yamashita, Masanori

AU - Yoshida, Haruyoshi

AU - Ichiyama, Satoshi

AU - Okabe, Hidetoshi

AU - Shigeta, Masayo

AU - Shimizu, Kaoru

AU - Masaki, Hiroya

AU - Heijyou, Hitoshi

AU - Nakaya, Hideo

AU - Takubo, Takayuki

AU - Kusakabe, Tadashi

AU - Higashiyama, Tomonori

AU - Yoshida, Hiroko

AU - Morishita, Hiroshi

AU - Matsuo, Shuji

AU - Kono, Hisashi

AU - Fukuda, Saori

AU - Sano, Reiko

AU - Yuzuki, Yosuke

AU - Ikeda, Norio

AU - Idomuki, Masaya

AU - Yamamoto, Go

AU - Kinoshita, Syohiro

AU - Kawano, Seiji

AU - Doi, Masao

AU - Watanabe, Yaeko

AU - Shimizu, Satomi

AU - Oka, Mikio

AU - Kobashi, Yoshihiro

AU - Kusano, Nobuchika

AU - Fujiwara, Hiromitsu

AU - Murota, Hiromi

AU - Morishita, Shota

AU - Nagai, Atsushi

AU - Moriyama, Hidehiko

AU - Taniguchi, Yuki

AU - Negayama, Kiyoshi

AU - Murao, Koji

AU - Miyamoto, Hitoshi

AU - Sugiura, Tetsuro

AU - Morita, Tamae

AU - Tou, Hiromi

AU - Matsunaga, Akira

AU - Kang, Dongchon

AU - Kiyosuke, Makiko

AU - Mashiba, Koichi

AU - Yanagihara, Katsunori

AU - Matsuda, Junichi

AU - Kohno, Shigeru

AU - Aoki, Yosuke

AU - Nagasawa, Zenzo

AU - Kusaba, Koji

AU - Hiramatsu, Kazufumi

AU - Saikawa, Tetsunori

AU - Miyanohara, Hiroaki

AU - Saeki, Yuji

AU - Takajo, Ichiro

AU - Okayama, Akihiko

AU - Yamane, Nobuhisa

AU - Nakasone, Isamu

N1 - Funding Information: * Associate Professor, Mississippi College School of Law. Many thanks to Professors Miriam Baer, Tamara Belinfanti, Mercer Bullard, Lisa Fairfax, Michelle Harner, Joan Heminway, Andrew Lund, Veronica Root, Victoria Shannon Sahani, Maurice Stucke, and Charles Yablon for their helpful input on an earlier draft of this paper during our Corporate Compliance Discussion Group at the 2014 Southeastern Association of Law Schools Annual Meeting. I offer a special thanks to Associate Professor Gregory Gilchrist and Assistant Professor Andrew Verstein for their detailed comments and suggestions, which have improved the Article immensely. I would also like to thank my research assistants, Jhasmine Andrews, Matthew Rich, Laura Barton, and Rita Santibanez for their excellent work on this project. Finally, I thank Mississippi College School of Law for the generous financial support provided for this project.

PY - 2012/6

Y1 - 2012/6

N2 - Postmarketing surveillance of levofloxacin (LVFX) has been conducted continuously since 1992. The present survey was performed to investigate in vitro susceptibility of recent clinical isolates in Japan to 30 selected antibacterial agents, focusing on fluoroquinolones (FQs). The common respiratory pathogens Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae continue to show a high susceptibility to FQs. In contrast, widely-prevailing resistance to macrolides was markedly noted among S. pneumoniae and S. pyogenes. Regarding H. influenzae, the prevalence of β-lactamase-negative ampicillin-resistant isolates has been increasing year by year (25.8% in 2002, 40.0% in 2004, 50.1% in 2007, and 57.9% in 2010). Enterobacteriaceae showed high susceptibility to FQs, however, prevalence of LVFX-resistant Escherichia coli, including intermediate resistance, was 29.3%, showing an increase over time. Nevertheless, the increase in the prevalence of LVFX-resistant E. coli isolates has slowed since 2007 (8.2% in 2000, 11.8% in 2002, 18.8% in 2004, 26.2% in 2007, and 29.3% in 2010), suggesting the influence of LVFX 500 mg tablets since its approval in 2009. Another Enterobacteriaceae member, Klebsiella pneumoniae, showed low resistance to FQs, in contrast with E. coli. In methicillin-resistant Staphylococcus aureus (MRSA), the percentage of FQ-susceptible isolates was low, at 51.6% for susceptibility to sitafloxacin, and at only around 10% for susceptibility to other FQs. However, methicillin-susceptible S. aureus (MSSA) isolates were highly susceptible to FQs, with the percentage ranging from 88.5% to 99.1%. The prevalence of FQs-resistant isolates in methicillin-resistant coagulase-negative staphylococci was higher than that in methicillin-susceptible coagulase-negative staphylococci, although it was lower than the prevalence of FQ-resistance in MRSA. The prevalence of FQs-resistant Pseudomonas aeruginosa isolates derived from urinary tract infections (UTIs) was 15.4-21.3%, higher than the prevalence of 6.1-12.3% in P. aeruginosa isolates from respiratory tract infections (RTIs). While this trend was consistent with the results of previous surveillance, gradual decreases were noted in the prevalence of FQ-resistant P. aeruginosa isolates derived from UTIs. The prevalence of multidrug-resistant P. aeruginosa was 2.3% among isolates derived from UTIs and 0.3% among isolates from RTIs, a decrease from the results of 2007, Acinetobacter spp. showed high susceptibility to FQs. Imipenem-resistant Acinetobacter baumannii, which is currently an emerging issue, was detected at a prevalence of 2.4% (13 isolates). Neisseria gonorrhoeae showed a high resistance of 81.3-82.5%, to FQs. Ceftriaxone (CTRX) continued to show 100% susceptibility until 2007, but the present survey revealed the advent of resistance to CTRX in some clinical isolates. The result of the present survey indicated that although methicillin-resistant staphylococci, Enterococcus faecium, P. aeruginosa from UTIs, N. gonorrhoeae, and E. coli showed resistance of about 20% or more (19.5-89.2%) against the FQs which have been used clinically for over 17 years, the trends observed were similar to the results of previous surveillance. While FQ resistance has been prevailing in E. coli, E. coli still shows more than 70% susceptibility to FQs. The other bacterial species maintained high susceptibility rates of greater than 80%, against FQs.

AB - Postmarketing surveillance of levofloxacin (LVFX) has been conducted continuously since 1992. The present survey was performed to investigate in vitro susceptibility of recent clinical isolates in Japan to 30 selected antibacterial agents, focusing on fluoroquinolones (FQs). The common respiratory pathogens Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae continue to show a high susceptibility to FQs. In contrast, widely-prevailing resistance to macrolides was markedly noted among S. pneumoniae and S. pyogenes. Regarding H. influenzae, the prevalence of β-lactamase-negative ampicillin-resistant isolates has been increasing year by year (25.8% in 2002, 40.0% in 2004, 50.1% in 2007, and 57.9% in 2010). Enterobacteriaceae showed high susceptibility to FQs, however, prevalence of LVFX-resistant Escherichia coli, including intermediate resistance, was 29.3%, showing an increase over time. Nevertheless, the increase in the prevalence of LVFX-resistant E. coli isolates has slowed since 2007 (8.2% in 2000, 11.8% in 2002, 18.8% in 2004, 26.2% in 2007, and 29.3% in 2010), suggesting the influence of LVFX 500 mg tablets since its approval in 2009. Another Enterobacteriaceae member, Klebsiella pneumoniae, showed low resistance to FQs, in contrast with E. coli. In methicillin-resistant Staphylococcus aureus (MRSA), the percentage of FQ-susceptible isolates was low, at 51.6% for susceptibility to sitafloxacin, and at only around 10% for susceptibility to other FQs. However, methicillin-susceptible S. aureus (MSSA) isolates were highly susceptible to FQs, with the percentage ranging from 88.5% to 99.1%. The prevalence of FQs-resistant isolates in methicillin-resistant coagulase-negative staphylococci was higher than that in methicillin-susceptible coagulase-negative staphylococci, although it was lower than the prevalence of FQ-resistance in MRSA. The prevalence of FQs-resistant Pseudomonas aeruginosa isolates derived from urinary tract infections (UTIs) was 15.4-21.3%, higher than the prevalence of 6.1-12.3% in P. aeruginosa isolates from respiratory tract infections (RTIs). While this trend was consistent with the results of previous surveillance, gradual decreases were noted in the prevalence of FQ-resistant P. aeruginosa isolates derived from UTIs. The prevalence of multidrug-resistant P. aeruginosa was 2.3% among isolates derived from UTIs and 0.3% among isolates from RTIs, a decrease from the results of 2007, Acinetobacter spp. showed high susceptibility to FQs. Imipenem-resistant Acinetobacter baumannii, which is currently an emerging issue, was detected at a prevalence of 2.4% (13 isolates). Neisseria gonorrhoeae showed a high resistance of 81.3-82.5%, to FQs. Ceftriaxone (CTRX) continued to show 100% susceptibility until 2007, but the present survey revealed the advent of resistance to CTRX in some clinical isolates. The result of the present survey indicated that although methicillin-resistant staphylococci, Enterococcus faecium, P. aeruginosa from UTIs, N. gonorrhoeae, and E. coli showed resistance of about 20% or more (19.5-89.2%) against the FQs which have been used clinically for over 17 years, the trends observed were similar to the results of previous surveillance. While FQ resistance has been prevailing in E. coli, E. coli still shows more than 70% susceptibility to FQs. The other bacterial species maintained high susceptibility rates of greater than 80%, against FQs.

UR - http://www.scopus.com/inward/record.url?scp=84865457403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865457403&partnerID=8YFLogxK

M3 - Review article

C2 - 23173294

AN - SCOPUS:84865457403

SN - 0368-2781

VL - 65

SP - 181

EP - 206

JO - Japanese Journal of Antibiotics

JF - Japanese Journal of Antibiotics

IS - 3

ER -